CTRI/2025/07/091428
Recruiting
Phase 4
A Phase IV, Multicenter, Non Comparative, Open Label Study Evaluating the Safety and Efficacy of Guselkumab Administered Subcutaneously in the Treatment of Indian Patients with Psoriatic Arthritis
Johnson and Johnson Private Limited9 sites in 1 country100 target enrollmentStarted: August 2, 2025Last updated:
Overview
- Phase
- Phase 4
- Status
- Recruiting
- Enrollment
- 100
- Locations
- 9
- Primary Endpoint
- Number of Participants With Adverse Events (AEs)
Overview
Brief Summary
The purpose of this study is to evaluate the safety and how well guselkumab treatment works (efficacy) in participants with psoriatic arthritis (PsA; a chronic, autoimmune form of arthritis that causes joint inflammation) who had inadequate response to standard therapies.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Masking
- None
Eligibility Criteria
- Ages
- 18.00 Year(s) to 99.00 Year(s) (—)
- Sex
- All
Inclusion Criteria
- •Participants who have definite diagnosis of active psoriatic arthritis (PsA) (according to the Classification criteria for Psoriatic Arthritis [CASPAR]) prior to the first administration of study drug and have at least 1 of the PsA.
- •subsets: distal interphalangeal joint arthritis, polyarticular arthritis with the absence of rheumatoid nodules, arthritis mutilans, asymmetric peripheral arthritis, or spondylitis with peripheral arthritis.
- •Participants who are negative for rheumatoid factors
- •Participants having inadequate response (defined by presence of active arthritis [presence of any swollen or any tender joint]) to standard therapies for 3 months at the highest recommended dose (e.g., conventional disease-modifying antirheumatic drugs [DMARDs] including methotrexate, apremilast, or nonsteroidal anti-inflammatory drugs [NSAIDs]), including biologics naïve patient or have failed, or were intolerant to one or more biological treatments [anti-TNF/IL-17i]
- •Participants are considered eligible per the following Tuberculosis (TB) screening criteria: 4a.
- •Have no history of TB prior to screening AND 4b.
- •Have no signs or symptoms suggestive of active TB upon medical history and/or physical examination AND 4c.
- •Have had no recent close contact with a person with active TB, or if there has been such contact, will be referred to a physician specializing in TB to undergo additional evaluation and, if warranted, receive appropriate treatment for latent TB prior to or simultaneously with the first administration of study drug AND 4d.
- •Within 6 weeks prior to the first administration of study drug, have a negative QuantiFERON- TB Gold and a negative tuberculin skin test result, OR have a newly identified positive QuantiFERON-TB Gold or tuberculin skin test result during screening in which active TB has been ruled out and for which appropriate treatment for latent TB has been initiated either prior to or simultaneously with the first administration of study drug AND 4e.
- •Have a chest radiograph (both posterior-anterior and lateral views), taken within 3 months prior to the first administration of study drug and read by a qualified radiologist, with no evidence of current active TB or old inactive TB
Exclusion Criteria
- •History of latent or active granulomatous infection prior to screening
- •Have a known clinically significant hypersensitivity to guselkumab or to any of the excipients
- •Have had a serious infection, or have been hospitalized for an infection, or have been treated with intravenous (IV) antibiotics for an infection within 2 months prior to first administration of study intervention
- •Has any known malignancy or has a history of malignancy, or a history of lymphoproliferative disease
- •Have received, or are expected to receive, any live virus or bacterial vaccination within 3 months before the first administration of study intervention, during the study, or within 6 months after the last administration of study intervention.
Outcomes
Primary Outcomes
Number of Participants With Adverse Events (AEs)
Time Frame: Up to 32 weeks
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily
Time Frame: Up to 32 weeks
have a causal relationship with the pharmaceutical/biological agent under study.
Time Frame: Up to 32 weeks
2. Number of Participants With Serious Adverse Events (SAEs)
Time Frame: Up to 32 weeks
A SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient
Time Frame: Up to 32 weeks
hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is
Time Frame: Up to 32 weeks
a congenital anomaly/birth defect; is a suspected transmission of any infectious agent via a medicinal product; is medically important.
Time Frame: Up to 32 weeks
Secondary Outcomes
- Percentage of Participants Who Achieve an American College of Rheumatology (ACR) 20 Response at Week 12.(Week 12)
- Percentage of Participants Who Achieve an ACR 20 Response at Week 24(Week 24)
- Change From Baseline in Analytic Marker of Inflammation (CRP Levels) at Weeks 12 and 24. CRP levels that is the analytic markers of inflammation will be assessed.(Week 12 and Week 24)
Investigators
Dr Sanish Davis
Johnson and Johnson Pvt Ltd
Study Sites (9)
Loading locations...
Similar Trials
Active, not recruiting
Phase 4
Investigation of tissue-resident memory T-cells and disease MEMory in psoriasis during GUSelkumab treatment. The GUSMEM study.2023-503776-25-00Aarhus University Hospital15
Active, not recruiting
Phase 3
A Phase 3 Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis2023-504719-34-00Janssen - Cilag International143
Active, not recruiting
Phase 3
A Study of Efficacy, Safety, and Pharmacokinetics of Guselkumab in the Treatment of Chronic Plaque Psoriasis in Pediatric Participants2023-503378-19-00Janssen - Cilag International97
Active, not recruiting
Phase 2
Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colitis2023-504743-13-00Janssen - Cilag International383
Recruiting
Not Applicable
A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe PsoriasisNCT07449234Janssen-Cilag Ltd.200